Regulus Therapeutics

Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection, and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy.

Regulus is also advancing several programs toward clinical development in renal, hepatic and central nervous systems diseases, both independently and with our strategic alliance partners.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
2007
Size (employees)
92 (est)-5%
Regulus Therapeutics was founded in 2007 and is headquartered in San Diego, US

Regulus Therapeutics Office Locations

Regulus Therapeutics has an office in San Diego
San Diego, US (HQ)
10614 Science Center Dr

Regulus Therapeutics Data and Metrics

Regulus Therapeutics Financial Metrics

Regulus Therapeutics's revenue was reported to be $1.2 m in FY, 2016 which is a 94% decrease from the previous period.
USD

Revenue (FY, 2016)

1.2 m

Revenue growth (FY, 2015 - FY, 2016), %

(94%)

Net income (FY, 2016)

(81.8 m)

EBIT (FY, 2016)

(81.5 m)

Market capitalization (21-Jul-2017)

49.8 m

Cash (31-Dec-2016)

14.9 m
Regulus Therapeutics's current market capitalization is $49.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

19.6 m7.7 m20.8 m1.2 m

Revenue growth, %

(61%)171%(94%)

Operating expense total

37.4 m52.6 m75.5 m82.7 m

EBIT

(17.8 m)(44.9 m)(54.8 m)(81.5 m)

EBIT margin, %

(91%)(586%)(264%)(6826%)

Pre tax profit

(18.7 m)(56.7 m)(55.8 m)(81.8 m)

Net Income

(18.7 m)(56.7 m)(55.7 m)(81.8 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

17.8 m37.3 m16 m14.9 m

Current Assets

117.2 m165 m134.3 m87.5 m

PP&E

3.8 m3.6 m5.4 m11.8 m

Total Assets

123.1 m171.5 m141.1 m100.7 m

Accounts Payable

1.2 m2.2 m2.7 m5.8 m

Current Liabilities

10.4 m35.2 m12.6 m13.8 m

Total Liabilities

44.6 m

Additional Paid-in Capital

172.5 m267.9 m315.7 m329.5 m

Retained Earnings

(79.1 m)(135.8 m)(191.5 m)(273.4 m)

Total Equity

93.5 m132 m124.1 m56.1 m

Financial Leverage

1.3 x1.3 x1.1 x1.8 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18.7 m)(56.7 m)(55.7 m)(81.8 m)

Depreciation and Amortization

1.4 m1.5 m1.6 m2.3 m

Accounts Payable

860 k940 k529 k3.1 m

Cash From Operating Activities

(28.3 m)(39.5 m)(49.9 m)(56.9 m)

Purchases of PP&E

(800 k)(1.1 m)(1.4 m)(913 k)

Cash From Investing Activities

(40.9 m)(29.2 m)21.5 m35.3 m

Cash From Financing Activities

46.5 m88.2 m7 m20.6 m

Interest Paid

37 k39 k(27 k)(981 k)

Income Taxes Paid

1 k1 k(1 k)(1 k)
USDY, 2016

Revenue/Employee

12.4 k

Financial Leverage

1.8 x

Regulus Therapeutics Operating Metrics

FY, 2016

Patents Issued

300

Regulus Therapeutics Market Value History

Regulus Therapeutics Online and Social Media Presence

Regulus Therapeutics News and Updates

Regulus Therapeutics Company Life and Culture

You may also be interested in